NXTS — Nexentis Technologies Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1789192 ·
Last close
$1.71
Market Cap
$2.49M
52W High
$23.80
52W Low
$1.43
ADV30
2,321,737
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -2,277,000 | -6,580,000 | 16,399,000 | 4,299,000 | 3,538,000 |
| Dec 2025 | -68,000 | — | -587,000 | 1,269,000 | 20,405,000 | 3,832,000 | 4,675,000 |
| Sep 2025 | 2,000 | 0 | -1,326,000 | 429,000 | 11,026,000 | 6,044,000 | 2,350,000 |
| Jun 2025 | 0 | -2,000 | -2,832,000 | -4,509,000 | 7,752,000 | 3,138,000 | 2,201,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-4,418,000
Investing CF
$-2,507,000
Financing CF
$8,520,000
CapEx
$-751,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-136.97
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-45,137,000
Inventory
$16,000
Receivables
$566,000
ST Investments
$1,902,000
EBIT TTM
$-10,742,000
Pretax Income TTM
$-9,803,000
Interest Exp TTM
$2,019,000
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -5,366,000 | -4,004,000 | 20,405,000 | 4,675,000 | — | -3,808,000 |
| Dec 2024 | 0 | -3,283,000 | -5,193,000 | 5,465,000 | 892,000 | — | -3,419,000 |
| Dec 2023 | 263,000 | -7,537,000 | -6,522,000 | 7,244,000 | 786,000 | — | -3,234,000 |
| Dec 2022 | 394,004 | -5,819,642 | -5,739,600 | 6,492,213 | 754,872 | — | -5,097,126 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BIXT | BIOXYTRAN, INC | $2.49M | $0.02 | — |
| CMND | Clearmind Medicine Inc. | $2.51M | $1.69 | — |
| GRI | GRI Bio, Inc. | $2.44M | $1.38 | — |
| SXTC | China SXT Pharmaceuticals, Inc. | $2.37M | $0.06 | — |
| CASIF | CASI Pharmaceuticals, Inc. | $2.67M | $0.13 | — |
News headlines (Yahoo Finance, 1h cache)
Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign
2026-07-28 12:06 · Yahoo
Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative
2026-07-07 12:25 · Yahoo
Nexentis Shares Rise After Solar Project Monetisation Agreement (NXTS)
2026-06-29 14:10 · Yahoo
Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment
2026-06-29 12:20 · Yahoo
Top Midday Decliners
2026-06-23 18:10 · Yahoo
Top Midday Gainers
2026-06-22 18:07 · Yahoo
Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery
2026-06-22 12:22 · Yahoo
Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases
2026-06-17 11:32 · Yahoo
Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development
2026-05-18 13:30 · Yahoo
Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone
2026-05-13 11:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.